retatrutide fat loss clinical trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Semaglutide vs tirzepatide vs retatrutide:
Description
10.3390/jcm12020672
Meanwhile, in mid-June 2024, she began tirzepatide 2.5 mg weekly subcutaneously, titrated to 7.5 mg after 3 weeks, to facilitate weight reduction (baseline 85 kg, BMI 28) prescribed by her family doctor
Together, these hormones coordinate to regulate appetite, insulin and glucagon secretion, and nutrient metabolism, making them central to metabolic health
Au HCT, Zheng YJ, Le GH, Wong S, Teopiz KM, Kwan ATH, Gill H, Badulescu S, Valentino K, Rosenblat JD, Mansur RB, McIntyre RS (2025) Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review
GLP-1 RAs also delay gastric emptying, and it is reasonable to consider alternative therapies that do not delay gastric emptying
The gut-brain connection deserves special mention
